Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Occult primary, version 3.2014.

Ettinger DS, Handorf CR, Agulnik M, Bowles DW, Cates JM, Cristea M, Dotan E, Eaton KD, Fidias PM, Gierada D, Gilcrease GW, Godby K, Iyer R, Lenzi R, Phay J, Rashid A, Saltz L, Schwab RB, Shulman LN, Smerage JB, Stevenson MM, Varadhachary GR, Zager JS, Zhen WK, Bergman MA, Freedman-Cass DA; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2014 Jul;12(7):969-74.

PMID:
24994917
2.

Comparison of histopathology to gene expression profiling for the diagnosis of metastatic cancer.

Kulkarni A, Pillai R, Ezekiel AM, Henner WD, Handorf CR.

Diagn Pathol. 2012 Aug 21;7:110. doi: 10.1186/1746-1596-7-110.

3.

A multicenter study directly comparing the diagnostic accuracy of gene expression profiling and immunohistochemistry for primary site identification in metastatic tumors.

Handorf CR, Kulkarni A, Grenert JP, Weiss LM, Rogers WM, Kim OS, Monzon FA, Halks-Miller M, Anderson GG, Walker MG, Pillai R, Henner WD.

Am J Surg Pathol. 2013 Jul;37(7):1067-75. doi: 10.1097/PAS.0b013e31828309c4.

4.

Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary.

Tothill RW, Li J, Mileshkin L, Doig K, Siganakis T, Cowin P, Fellowes A, Semple T, Fox S, Byron K, Kowalczyk A, Thomas D, Schofield P, Bowtell DD.

J Pathol. 2013 Dec;231(4):413-23. doi: 10.1002/path.4251.

PMID:
24037760
5.

Management of the unknown primary carcinoma: long-term follow-up on a negative PET scan and negative panendoscopy.

Miller FR, Karnad AB, Eng T, Hussey DH, Stan McGuff H, Otto RA.

Head Neck. 2008 Jan;30(1):28-34.

PMID:
17657782
6.

Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary.

Horlings HM, van Laar RK, Kerst JM, Helgason HH, Wesseling J, van der Hoeven JJ, Warmoes MO, Floore A, Witteveen A, Lahti-Domenici J, Glas AM, Van't Veer LJ, de Jong D.

J Clin Oncol. 2008 Sep 20;26(27):4435-41. doi: 10.1200/JCO.2007.14.6969.

PMID:
18802156
7.

Gene expression profiling in patients with carcinoma of unknown primary site: from translational research to standard of care.

Hainsworth JD, Greco FA.

Virchows Arch. 2014 Apr;464(4):393-402. doi: 10.1007/s00428-014-1545-2. Epub 2014 Feb 1. Review.

PMID:
24487792
8.

Gene expression profiles help identify the tissue of origin for metastatic brain cancers.

Wu AH, Drees JC, Wang H, VandenBerg SR, Lal A, Henner WD, Pillai R.

Diagn Pathol. 2010 Apr 26;5:26. doi: 10.1186/1746-1596-5-26.

9.

Cancer of unknown primary site: evolving understanding and management of patients.

Greco FA.

Clin Adv Hematol Oncol. 2012 Aug;10(8):518-24. Review.

PMID:
23073050
10.

New strategies for carcinoma of unknown primary: the role of tissue-of-origin molecular profiling.

Varadhachary G.

Clin Cancer Res. 2013 Aug 1;19(15):4027-33. doi: 10.1158/1078-0432.CCR-12-3030. Epub 2013 Mar 21.

11.

Cancer from an unknown primary site.

Dowell JE.

Am J Med Sci. 2003 Jul;326(1):35-46. Review.

PMID:
12861124
12.

Comparison of histopathological and gene expression-based typing of cancer of unknown primary.

Morawietz L, Floore A, Stork-Sloots L, Folprecht G, Buettner R, Rieger A, Dietel M, Huebner G.

Virchows Arch. 2010 Jan;456(1):23-9. doi: 10.1007/s00428-009-0867-y. Epub 2009 Dec 10.

PMID:
20012089
13.
14.

Prediction of Primary Tumors in Cancers of Unknown Primary.

S√łndergaard D, Nielsen S, Pedersen CNS, Besenbacher S.

J Integr Bioinform. 2017 Jul 7;14(2). pii: /j/jib.2017.14.issue-2/jib-2017-0013/jib-2017-0013.xml. doi: 10.1515/jib-2017-0013.

15.

NCCN Clinical Practice Guidelines Occult primary.

Ettinger DS, Agulnik M, Cates JM, Cristea M, Denlinger CS, Eaton KD, Fidias PM, Gierada D, Gockerman JP, Handorf CR, Iyer R, Lenzi R, Phay J, Rashid A, Saltz L, Shulman LN, Smerage JB, Varadhachary GR, Zager JS, Zhen WK; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2011 Dec;9(12):1358-95.

PMID:
22157556
16.

Diagnosis of metastatic neoplasms: molecular approaches for identification of tissue of origin.

Monzon FA, Koen TJ.

Arch Pathol Lab Med. 2010 Feb;134(2):216-24. doi: 10.1043/1543-2165-134.2.216. Review.

PMID:
20121609
17.

Unknown primary tumors.

Natoli C, Ramazzotti V, Nappi O, Giacomini P, Palmeri S, Salvatore M, Landriscina M, Zilli M, Natali PG, Tinari N, Iacobelli S.

Biochim Biophys Acta. 2011 Aug;1816(1):13-24. doi: 10.1016/j.bbcan.2011.02.002. Epub 2011 Mar 1. Review.

PMID:
21371531
18.

Cancer of unknown primary: from immunohistochemistry to gene expression profiling.

Chiang WM, Kapadia M, Laver NV, Nystrom JS.

J Clin Oncol. 2012 Oct 10;30(29):e300-2. doi: 10.1200/JCO.2011.41.1827. Epub 2012 Sep 10. No abstract available.

PMID:
22965966
19.

Occult primary malignancies.

Yeomans AC, Washington JB.

Oncol Nurs Forum. 1991 Apr;18(3):539-44.

PMID:
2057397
20.

Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute.

Hainsworth JD, Rubin MS, Spigel DR, Boccia RV, Raby S, Quinn R, Greco FA.

J Clin Oncol. 2013 Jan 10;31(2):217-23. doi: 10.1200/JCO.2012.43.3755. Epub 2012 Oct 1.

PMID:
23032625

Supplemental Content

Support Center